Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Benzinga · 1d ago
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.